The recent article of O'Brart et al.
The recent article of O'Brart et al. 1 discussed the roles of riboflavin concentration (in the stroma) on the efficacy of corneal collagen crosslinking (CXL). Clinical studies of Ng et al. 2 showed that accelerated CXL (ACXL) had less efficacy than standard CXL (SCXL) for the same fluence (dose) based on Bunsen-Roscoe reciprocal law (BRL). To overcome this intrinsic drawback of ACXL, Lin 3 5 showed that S2 follows BRL and is proportional to the light dose (E 0 ) and C[O 2 ]. In contrast, non-BRL feature occurs in type-I CXL (or S1) to be analyzed late. In contrast to the conventional belief that oxygen-mediated type-II plays the critical role of CXL, the kinetic model of Kamaev et al. 6 showed that CXL is predominated by type-I, whereas oxygen (or type-II) plays only a limited and transient role. Lin's 3-pathway model 5, 7 showed mathematical details of the role of oxygen, supporting the claim of Kamaev et al. 6 Moreover, a recent clinical study of Lombardo et al. 8 showed a simpleexponential temporal profile of Rf concentration that implied that, in ambient environment, non-oxygen-mediated type-I mechanism is predominant.
For type-I CXL, the S-function (S1) is shown in the Table, where F(z)C 0 is the initial (at t ¼ 0) Rf concentration (in the stroma) having a depth-profile defined by a diffusion depth (D),
In contrast to type-II (S2), in which oxygen plays a transient but critical role, type-I (S1) does not require oxygen and it is the predominant pathway of CXL efficacy. [4] [5] [6] [7] [8] At steady-state (with btX>>1), S1 follows a nonlinear scaling law 4 that S1 is proportional to (FC 0 /I 0 ) 0.5 exp(0.5Az), or S1a[C 0 ] 0.5 (for z ¼ 0) and stronger dependence of S1a[C 0 exp(Az)] 0.5 (for z > 0), because A is also proportional to C 0 . For example, on corneal surface (or z ¼ 0), when C 0 is doubled (from 0.1% to 0.2%), S1 increases by a factor of 1.43. The Figure shows the theoretical Rf dose-curve (or S1 versus C 0 ) comparing to the data of O'Brart et al. 1 (their Fig. 3A , normalized, and fit at 0.1%); both show the nonlinear feature of S1aC 0 0.5 . CXL depth (defined by when S1 is maximal) is given by 7 z* ¼ ln(NE 0 )/A, with N being a numerically fit constant given by N ¼ 0.16 (for D >>1 cm) and N ¼ 0.224 (for D ¼ 500 lm). For example, when C 0 is doubled (from 0.1% to 0.2%), A increases and z* is reduced by 1.48 times. The z*-formula shows that higher Rf concentration results in an increased (or larger S1), but more superficial (or small z*) crosslinking effect, as also indicated by O'Brart et al. 1 Our formulas lead to a new criterion of CXL efficacy based on the product of CXL [strength] (or S1) and [depth] (or z*), that is, the [volume] of stroma being crosslinked. For a given C 0 , deeper CXL may be achieved by larger fluence (E 0 ). However, to achieve clinically acceptable CXL efficacy by a minimal E 0 , one requires an optimal range of C 0 . For example, C 0 ¼ 0.15% to 0.3%, and E 0 ¼ 3.5 to 4.5 J/cm 2 , such that [depth], z* ¼ 200 to 300 lm, and [strength], S1 ¼ 1.5 to 2.0, or CXL efficacy Eff ¼ 1 -exp(-S1) ¼ 0.78 to 0.86. Our formulas also demonstrate that epi-on CXL (having a smaller D and C 0 ) is less efficient than epi-off CXL, as clinically reported. To conclude, the author would like to see further basic, clinical investigations to support the presented formulas, as suggested by the reviewers.
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